Cronos Group Inc. (CRON) Earnings Call Transcript & Summary
February 29, 2024
Earnings Call Speaker Segments
Operator
operatorGood morning, everyone. I'm Josh, and I'll be handling the conference operator duties for you today. I'd like to extend a welcome to all of you on this call covering Cronos' fourth quarter and full year 2023 earnings. This session is being recorded as it happens. Right now, I'll hand things over to Shayne Laidlaw from Investor Relations. Shayne, the floor is yours.
Shayne Laidlaw
executiveThanks, Josh, and I appreciate everyone being here today as we go through Cronos' financial and business results for the 2023 fourth quarter and the full year. With me today are Mike Gorenstein, our Chairman, President and CEO, and James Holm, our CFO. This morning Cronos put out a news release announcing our financial results, and it has been filed on our EDGAR and SEDAR profiles. That information, along with the prepared remarks, will be posted on our website in the Investor Relations section as well. What we're presenting on this call is preliminary and could change before the company's audited consolidated financial statements get filed with the SEC, and we expect that filing to happen later today. Before handing things over to Mike, I want to remind everyone that we may make forward-looking statements and refer to non-GAAP financial measures on this call. Such forward-looking statements rest on management's current expectations and assumptions, and they carry risks and uncertainties that might cause actual results to differ materially from what those forward-looking statements project. The factors that could make actual results differ materially from expectations are laid out in our earnings materials and in our SEC filings available on our website, and any forward-looking statements we make on this call are qualified in their entirety by those documents.
Shayne Laidlaw
executiveDetails on non-GAAP financial measures, along with reconciliations to U.S. GAAP, are also available in our earnings materials posted on our website. And finally, throughout this conference call we'll be making statements about market share information, and unless otherwise stated, Hifyre provides all market share data. We'll now deliver prepared remarks, and after that we'll move into a question-and-answer session. With that, I'll hand things over to Cronos' Chairman, President and CEO, Mike Gorenstein.
Mike Gorenstein
executiveThanks, Shayne, and good morning to all of you. Looking back at 2023, I feel tremendous pride in the entire Cronos team, because we have guided this company through a wide range of transformational changes. Beyond having products that are winning in the marketplace, we have put Cronos in a strong position to seize opportunities in 2024. We captured $30 million in operating expense savings in 2023, which came in above the target of $20 million to $25 million we had previously stated. After that $5 million overachievement in savings in 2023, we expect to save an additional $5 million to $10 million in 2024. We exited our U.S. CBD operations so we could focus on adult-use products, and we signed a sale leaseback agreement covering our Peace Naturals Campus in Stayner, for which we anticipate receiving $17 million, and we wound down operations at our Winnipeg facility, which is currently listed for sale. These changes culminated in significant cash flow improvement, and we stayed laser-focused on organic growth. We grew the Spinach brand into the #2 brand by market share in Canada, propelled by #1 rankings in the flower and edible categories. We launched the Lord Jones brand in Canada, opened 2 international markets, Germany and Australia, and continue to navigate our business through the war in Israel.
Mike Gorenstein
executiveCash and equivalents rose about $22 million between Q3 and the latest quarter, reaching around $862 million, thanks to lower operating expenses, higher interest income, and better working capital. Cronos holds the industry's strongest balance sheet in cannabis, and we keep managing our capital responsibly while preserving our capacity to launch innovative borderless products and to build a blueprint for selling into other cannabis markets as they open up. Beginning with our expanding international business: we kept scaling up with Cansativa, our German distribution partner and a top distributor of medical cannabis in Germany. Cansativa runs a network of roughly 2,000 pharmacies that today serve about 300,000 patients in Germany's medical market. Our Peace Naturals flower products have swiftly earned patient attention and loyalty, lifting Peace Naturals into a leading brand position in the German market, powered by winning genetics from our in-house breeding program, including GMO Cookies and Wedding Cake. Just weeks after launch, our GMO Cookies flower SKU captured a leading market share position in Germany. Reentering the German market marked a significant milestone for Cronos, and we look forward to broadening our reach and brand awareness with Cansativa's help. On Friday, Germany's Chief legislative body approved a cannabis bill that opens up the cannabis market in Germany, including no longer classifying cannabis as a narcotic.
Mike Gorenstein
executiveWith this shift, we can market more effectively to patients and tap into the substantial growth runway the market offers. In our view, Cronos is well positioned, thanks to a leading distributor and best-in-class genetics, to seize the growth that potential legislative changes could fuel. Now turning to Australia. We keep working alongside our partner, Vitura Health, in which Cronos holds roughly 10% of the common shares. The Australian market has expanded considerably over the past 3 years, hitting approximately $200 million in retail sales in 2023 per BDS Analytics, and supply there is another achievement Cronos pursued in the back half of 2023. We're eager to collaborate closely with our partners at Vitura to give patients high-quality cannabis products. Entering the German and Australian markets was a positive way to close out the back half of 2023, and we expect these to be growth drivers for us in 2024. As 2024 moves forward and new markets open and develop, Cronos will keep seeking additional international growth opportunities. We have a leading flower breeding program and an innovation pipeline that wins in the Canadian market, and we're keen to bring these to a broader subset of patients and consumers around the world.
Mike Gorenstein
executiveTurning to Israel now. Even with the difficulties the war has created, the people we work with there have demonstrated remarkable strength and determination. They keep driving the business ahead in spite of the conflict, the geopolitical situation, and conditions in the market. Fueled by the breeding work we do in genetics, Peace Naturals remains a top brand in that market, with items like GMO and Wedding Cake out in front. As we move into additional markets, these genetics keep confirming they are winners. We introduced a new brand in early January under the name Lit. Lit carries a distinct marketing position, with a price point that is easier to reach, all while preserving the quality that has come to be associated with the products we already have on the market. After patient growth stayed flat through most of 2023, the fourth quarter brought a recovery in growth, which gave the industry a helpful tailwind. At the same time, the regulator, the Yakar, is examining a major revision of cannabis rules that would step by step make access simpler for patients through a shift to a prescription model and by making cannabis a first-line treatment choice for doctors handling particular disease indications. A patient base that is expanding—it now stands above 140,000—combined with possible regulatory change, could open up growth for the industry, and we are positioned well to capitalize on it.
Mike Gorenstein
executiveNow moving to Canada. In Q4, we kept carrying out our strategy of building a strong lineup of borderless products, with new launches and solid market results standing out. By the end of 2023, our Spinach brand held the #1 spot among flower brands in Canada, with a 6.9% market share during the fourth quarter, rising from being the 4th ranked brand in 2022. That result comes after years of genetic breeding work, R&D spending, and top-tier large-scale cultivation through our JV Cronos GrowCo, which has set our products apart in the field. We secured a leading flower position alongside a strong year of growth and innovation for the Spinach product portfolio, which as of December 2023 ranks as the second best growing cannabis brand in Canada across all categories. On the edible side, Spinach edibles represented 16.2% of retail sales in that market during the fourth quarter, so we remain the leader in edibles. We have a fantastic product that keeps introducing new flavor profiles in cannabinoid blends — a perfect illustration of a borderless, scalable product. All told, 4 of our edible products sit in the top 15 by market share. The Spinach brand also just introduced its Strawberry Kiwi 5:1 CBD/THC SOURZ gummy.
Mike Gorenstein
executiveThe goal behind these gummies was to go head-to-head with other CBD edible offerings, and they've been finding success in the market—plus the 10-pack gives people a way to share these lower-THC edibles with friends. Earlier this month, our Lord Jones brand rolled out Chocolate Fusions, which marks an exciting debut in the chocolate edibles space. This latest edible innovation from Cronos was developed and crafted by a skilled team of culinary chefs, food scientists and leaders in cannabis product development. The bite-size Chocolate Fusions offer a dynamic multi-texture experience that brings together a soft, chewy center, crunchy infusions and an outer layer of rich, creamy chocolate, delivering a decorative sweet treat for adult consumers. In our view, Chocolate Fusions is a category-defining product that will grow the chocolate segment. Chocolate Fusions deliver what adult consumers have come to expect from our brands: truly differentiated, consistent, high-quality products that introduce new and unexpected ways to consume and experience cannabis. We're looking forward to growing the Lord Jones brand in Canada and building a bold, premium portfolio that changes the future of what's possible in cannabis innovation. Turning to vapes—I'm really excited about our efforts and the success we're seeing in this category.
Mike Gorenstein
executiveOur market share position improved to #3, and in Q4 we grew to 7.7% of the market. Over the past year we've put substantial effort into our vape portfolio, and seeing these strong market results is terrific. During 2024, we'll keep evolving the vape category by giving consumers flavor-forward profiles and rare cannabinoid combinations, like our new 1.2 gram format, which drove a large portion of the quarter's gains. In January 2024, we introduced Lord Jones live resin vapes in 2 different hardware options. The lineup offers versatile sizes — a half gram trial size, the convenience of an all-in-one device, and the 1 gram stock-up size as a 510-thread cartridge — serving both enthusiasts and people new to the category. Designed with the discerning cannabis consumer in mind, these products reflect a dedication to excellence, delivering an unmatched mix of curated strains, pure live resin and high-quality hardware. I take immense pride in these new products, and we expect them to help us reach more of the vape category in 2024. We're also continuing to enhance and push innovation in our Spinach pre-roll portfolio with several new infused products, among them pink lemonade, peach punch and strawberry slurricane.
Mike Gorenstein
executiveCompared with the prior year, our pre-roll retail sales rose 137% during the fourth quarter. During Q4, we introduced a Spinach Feelz Full Tilt THCV pre-roll into the infused pre-roll range. Thanks to its THC and THCV combination, this pre-roll delivers a stronger, more elevated high, and it pairs well with the THCV vape and gummy items we already offer. In Q4, we also brought the Lord Jones Ice Water Hash Fusions pre-rolls to market. Among adult consumers, hash products are gaining popularity within premium pre-rolls. The leading solventless infusion is ice water hash, which ranks as the second most popular infusion overall in the pre-roll category. An optimized ratio of premium high potency flower and complementary solventless ice water hash goes into crafting these pre-rolls, preserving the buds' natural terpenes, and each is fitted with a reusable ceramic tip that helps cool the smoke. Extensive research and sensory testing has gone into these new products so they deliver a smoother experience with bold flavors. In the Alberta and DC markets, both the White Tahoe and Cosmic Kush strains of our Lord Jones infused pre-rolls are selling well. We're excited about further growth once the pre-rolls are available more widely across Canada during this year. Given our award-winning pre-rolls and our strong position in dry flower, we're confident we can keep growing in this category under both the Lord Jones and Spinach brands through innovations and quality product offerings.
Mike Gorenstein
executiveNow, on our Canadian cultivation joint venture. GrowCo keeps delivering strong cultivation results. For the fourth quarter, GrowCo told us it had preliminary unaudited revenue of roughly $6.6 million from customers other than Cronos. On top of that, the credit facility Cronos extended to GrowCo earlier still carries $69.8 million outstanding, after GrowCo repaid $5.6 million of principal in 2023. GrowCo also paid $10.3 million in interest during 2023. GrowCo's healthy financial results — which generate equity pickup, interest payments and loan repayment to Cronos — are an essential piece of our overall financial picture. Now to the U.S. market. We're glad to hear growing momentum behind reclassifying cannabis. No matter how exactly federal regulation and commercialization of cannabis products play out, rescheduling would be a meaningful step in the right direction for U.S. cannabis, and we hope that momentum continues in 2024. This year's success has produced significant operating expense savings and a substantial cash flow improvement, which leaves us better positioned to build a portfolio of borderless products backed by strategic infrastructure and global partnerships. Our long-term strategy — investing in brand innovation while staying asset-light — is working, and we're only getting started. Together, these efforts and an industry-leading balance sheet put us in a good position to execute in any market.
Mike Gorenstein
executiveHaving said that, I'll now hand things over to James, who will walk you through our financials.
James Holm
executiveThanks, Mike, and good morning, everyone. Before diving into the fourth-quarter details, I'll walk through our full year 2023 results at a high level. During 2023, net revenue rose 1% year-over-year to $87.2 million, driven by strong performance in Canada and the start of sales to Germany and Australia, offset by a slowdown in Israel. On a constant currency basis, consolidated net revenue grew 6% to $91.7 million. Total operating expenses fell by $30 million compared with the prior year. Adjusted EBITDA came in at negative $61 million, an improvement of 12%, and operating cash flow improved by $46 million to negative $43 million. Now I'll turn to our fourth quarter 2023 results versus the prior year period. Consolidated net revenue was $23.9 million, up 9% from the prior year. Constant currency consolidated net revenue rose 11% to $24.5 million. The increase came primarily from higher cannabis flower sales in Canada and cannabis shipments to Germany and Australia, partly offset by lower cannabis flower sales in Israel stemming from the war and competitive activity, along with an adverse price mix in the Canadian cannabis flower category that drove higher excise tax payments as a percentage of revenue.
James Holm
executiveFourth-quarter gross profit came in at $1.9 million, which works out to an 8% gross margin — that's a $0.7 million gain versus the same period a year earlier. The main drivers there are stronger sales in Canada along with ongoing work to optimize the supply chain. Now turning to the full-year margin. Through the first 9 months we performed well, and the standout was a stable margin range of 15% to 16% all the way through the third quarter. Sadly, the war in Israel and stepped-up competitive activity both took a toll on margins. As we head into 2024 with a leaner operational footprint, our efforts are focused on further supply chain optimization and bringing automation into our production processes so we can boost throughput and take costs out of the system, and that ought to lift margins as the year goes on. Our expectation is that as 2024 progresses, we'll bounce back from the fourth-quarter result and build on the success achieved during the first 9 months of 2023. Consolidated adjusted EBITDA for the fourth quarter was negative $14.8 million, an improvement of $4.2 million over the prior year. That gain was mainly the result of lower general and administrative and research and development expenses, plus better gross profit.
James Holm
executiveAfter we raised our operating expense savings target to $20 million to $25 million in Q2 2023, we're happy to report that we exceeded the top of that range by $5 million, reaching $30 million in operating expense savings. Because we overachieved on savings in 2023, we are revising our 2024 savings projections to deliver an incremental $5 million to $10 million. Now turning to the balance sheet. The company finished the quarter with roughly $862 million in cash and short-term investments, which is up by about $22 million from the third quarter. Along with delivering on operational efficiencies and maximizing the return on our cash, we received an interest payment on our GrowCo senior secured loan of $1.9 million and a principal repayment of $1.4 million, for total cash paid by GrowCo to Cronos of $3.3 million in Q4. Altogether, for 2023, we received $10.3 million in interest payments and $5.6 million in principal payments. Having the best balance sheet in the cannabis industry enables us to take calculated strategic bets while we remain steadfastly focused on reducing cash burn. Moving to the cash flow statement. Cash flow from operations was positive at approximately $16.8 million, representing a substantial improvement.
James Holm
executiveAlso, free cash flow — which we calculate as operating cash flow minus CapEx — came in at a positive $15 million, which is another terrific accomplishment. There are plenty of wins we can highlight: gains in market share, cuts to OpEx, better optimization of our cash balance, and strengthening cash flow from operations, and we are reaffirming our guidance that we expect the net change in cash — defined as the total of cash and cash equivalents plus short-term investments — to be positive in 2024. Reflecting on all these improvements, I share Mike's confidence in where the business is headed and in how ready we are to enter new markets as they become available. With that, I'll hand it back to Mike.
Mike Gorenstein
executiveThanks, James. For Cronos, 2023 proved to be a standout year. We keep reshaping the company and adjusting it to the current realities of our sector. Our brands are succeeding around the world, and that comes from the dedication of our staff in delivering best-in-class borderless products to the market. Overall, Spinach ranks as the #2 brand and sits at #1 in flower as well as edibles. We introduced Lord Jones in Canada, taking the brand back to its cannabis origins with a suite of innovative, high-quality products, and we are eager to keep building. Before we take questions, I want to establish clearly what sits beneath the Cronos umbrella and where we are right now. We ended the year holding roughly $862 million in cash and short-term investments, with 0 debt. Interest income in Q4 came to more than $14 million, and for 2024 we expect to produce somewhere around $40 million to $50 million in interest income. Within Canada, our Spinach brand ranks as the second most popular brand. We introduced the Lord Jones brand into the Canadian adult use cannabis market with products we are confident can succeed. In Israel we have a leading medical brand, Peace Naturals, which recorded $21.1 million in net revenue in 2023.
Mike Gorenstein
executiveDuring 2023's fourth quarter, cannabis shipments went out to Germany and Australia, which broadened the reach of our business around the world. Our holdings include a 5.9% interest in PharmaCann, among the biggest MSOs in the U.S., carried on our books at $26 million. Half the equity of Cronos GrowCo belongs to us; that business is profitable, and in 2023 GrowCo made principal and interest payments to us totaling $15.9 million. We hold roughly a 10% stake in Vitura, Australia's top medical cannabis firm, valued on our books at $9.6 million. Last, we enjoy an exclusive global partnership with Altria. Having steadied our cash balance and sharply bettered the trajectory of our cash flow, we now rank among the cannabis companies best positioned to capitalize on fresh opportunities for market growth. We enter this new fiscal year with energy and readiness to bring Cronos into its next chapter. That said, I'll open the line for questions.
Operator
operator<<operator_script>> The initial question will be from John Zamparo at CIBC Capital Markets.
John Zamparo
analystLet me begin with gross margin. You listed a few factors behind that figure coming in below Q3. Could you put those in order of importance? And then, regarding the initiatives you flagged for next year—automation and a handful of other things—does the gain from those sit inside your cost savings target for '24, or would it come on top of it?
James Holm
executiveThanks, John. So across the first 9 months of the year, we delivered steady results, with gross margin coming in between 15% and 16%. If you set aside the inventory write-downs, we saw steady improvement, more or less, as the year went on — the exception being Q4. Sadly, because of the war in Israel and heightened competitive activity, margins took a negative hit. As we progress through 2024, we do expect to bounce back from that fourth quarter and to build on the success achieved during the first 9 months. The positive drivers for gross margin in the quarter will keep coming from our cannabis extracts category, which has a higher margin profile and gains from lower cannabis biomass costs as we keep leveraging the GrowCo joint venture, along with better fixed cost absorption in our Canadian supply chain as we keep growing the business and further optimizing supply chain costs. In addition, the announced exit of our Winnipeg facility is expected to generate extra COGS savings in 2024, adding to the $5 million to $10 million savings target for '24. And then, John, as you alluded to, there's some further opportunity we're pursuing by driving automation into the supply chain.
James Holm
executiveSo a portion of that is already factored in as further possible upside as well across the year.
John Zamparo
analystUnderstood. All right, that's useful. So for my second question, there are 2 parts. I'd really like to hear your perspective on Australia and Germany separately, especially with regard to Cronos. Australia looks appealing to quite a few different LPs, and it's getting more crowded. Do you believe that market can sustain its growth? Are there entry barriers that would stop additional players from coming in? And regarding Germany, how much upside do you see for Cronos, given that you've gone with the distributor model in light of the recent legislative change?
Mike Gorenstein
executiveSure, thank you, John. So I think if you look at the Australian and German markets, they were similar in size last year, with Australia being somewhat bigger, and you see pretty comparable hurdles in other international markets, just in terms of having the kind of supply chain and what you need to ensure products cross borders and meet really tight specifications. For us, as in other markets, what will really count is having excellent genetics and making sure those genetics are cultivated very well. And so what has driven us to lead in Israel and Canada and Germany is what we expect will let us succeed there. Regarding growth relative to Germany, I think just given the country's size, I wouldn't expect it to keep outpacing Germany, but I do think there is still runway ahead. In Germany, we already expected degrowth, but a week ago, having to vote on changing how cannabis is treated, it is a bill that opened up the cannabis market and is no longer classified as a narcotic. And I think that is really significant because while people may talk about adult use or compassion clubs and what that might mean, really, for us, what this means is we are now allowed to effectively market medical cannabis.
Mike Gorenstein
executiveThat represents a meaningful shift, and I anticipate substantial growth in Germany. From an international market standpoint, that is the narrative I believe should unfold during the coming year.
Operator
operatorThe next person to ask something is Bill Kirk at ROTH MKM.
Bill Kirk
analystYou mentioned heightened competition as a headwind to margins. Were there particular formats or provinces where that uptick in competitive activity showed up?
James Holm
executiveYes. Thanks for asking. Overall, I'd say we saw competition everywhere, and what we were mainly referring to there was rivalry in Israel that the war has been driving. So many of our competitors are basically facing the same challenges we are right now. There are supply chain problems in that market. Fortunately, our facility wasn't hit directly, and our workforce there is extremely resilient. So we've worked hard to stabilize operations, keep producing, and make sure we're delivering our best-in-class products to the end consumer. We do see a bit of competition in Canada too. But I think in Canada, you're pointing out that despite that competition, right, we hold the #1 spot in flower, #1 in edible, #3 in vape and #8 in pre-roll, and those positions are steadily improving. So we feel very confident about our portfolio and about the products and innovation we're bringing to market.
Bill Kirk
analystAnd then, as a follow-up on Germany, why is it that the modifications there would support expansion of the medical market instead of — if cannabis isn’t classified as a narcotic, why wouldn’t they designate it the adult-use — unstructured adult-use market, and wouldn’t that take share away from the existing medical market, right? Could you help me sort of work through that — give it a little thought?
Mike Gorenstein
executiveAbsolutely, that’s a really good question. If you look at how cannabis has been handled in Europe compared with North America, the two are entirely different. When you consider medical cannabis in the U.S., it isn’t truly operating through anything like a pharmaceutical-style system. And in Germany, it has genuinely been handled as a narcotic, which means an extremely, extremely restrictive marketing regime. Changing that and letting you actually communicate with patients about the benefits of having a superior product from us, I think, is a game changer. And what people refer to as the adult-use program in Germany isn’t really a commercial adult-use program. You can’t have the same kind of infrastructure that exists in Canada or Germany, and there aren’t actual legal adult-use sales. It’s really only reducing the penalties in listed adult-use markets. And with that, I think you shouldn’t expect to see quality products coming out, or improved access to quality products. So it will split the so-called illicit market from a premium medical market. And when you add the ability to advertise and market on top of that, I think it’s steering people toward premium product.
Operator
operator<<operator_script>> The following question is from Yewon Kang at Canaccord Genuity.
Yewon Kang
analystYewon Kang here, speaking for Matt Bottomley. I’d like to dig a bit deeper into the gross margin issue. My question concerns the adjusted EBITDA loss, which was fairly steady this quarter. Is it possible that some expenses were reclassified between operating expenses and COGS, which would have caused the gross margin profile to fall off while the adjusted EBITDA loss stayed stable this quarter?
James Holm
executiveYes. Thanks for asking. So, as we said, the main factor was really Israel and the tougher competition there stemming from the war, plus some inventory write-downs tied to that. So that's really the primary thing behind it.
Yewon Kang
analystAll right, understood. Regarding the Lord Jones launch — I realize it happened just a couple of months back — but could you speak to the early consumer response you're seeing throughout Canada, and also what the bud peddlers are telling you about the brand?
Mike Gorenstein
executiveAbsolutely. Thank you. Yeah, I'd say it's gone quite well. As you pointed out, the launch has been limited in size up to now. Still, we're choosing to move in a highly tailored and careful way, and on the distribution side we are seeing reorders come in. Demand is strong, particularly for the hash infused pre-rolls, which are showing up at the top of the category. So that has us quite excited. There's also a great deal of anticipation, I believe, especially considering how well SOURZ for Chocolate Fusions has done — we truly expect that to become a crown jewel portfolio, something capable of not only defining the category but also moving the broader chocolate category ahead to the point where we can get it — it ought to be — positioned within edible.
Operator
operatorThanks. That brings us to the end of the conference call. We appreciate everyone taking part. You're free to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.